Nurix Therapeutics, Inc. (NRIX) stock
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$14.10−0.14 (-0.98%)
Close on Nov 18, 2026Market cap $1.54BP/E 6.1Yield 0.00%
Nurix Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Nurix Therapeutics's free cash flow for the twelve months ending Aug 31, 2026 was $369.81M. For fiscal 2025 it was -$263.47M. The highest annual figure on record is -$1.05M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | -$263.47M | – |
| FY2024 | Nov 30, 2024 | -$181.86M | – |
| FY2023 | Nov 30, 2023 | -$89.77M | – |
| FY2022 | Nov 30, 2022 | -$172.05M | – |
| FY2021 | Nov 30, 2021 | -$90.03M | – |
| FY2020 | Nov 30, 2020 | -$4.63M | – |
| FY2019 | Nov 30, 2019 | -$1.05M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Aug 31, 2026 | $614.24M | – |
| Q2 FY2026CQ2 2026 | May 31, 2026 | -$98.51M | – |
| Q1 FY2026CQ1 2026 | Feb 28, 2026 | -$72.96M | – |
| Q4 FY2025CQ4 2025 | Nov 30, 2025 | -$72.96M | – |
| Q3 FY2025CQ3 2025 | Aug 31, 2025 | -$60.10M | – |
| Q2 FY2025CQ2 2025 | May 31, 2025 | -$65.84M | – |
| Q1 FY2025CQ1 2025 | Feb 28, 2025 | -$64.57M | – |
| Q4 FY2024CQ4 2024 | Nov 30, 2024 | -$50.86M | -311.0% |
| Q3 FY2024CQ3 2024 | Aug 31, 2024 | -$44.52M | – |
| Q2 FY2024CQ2 2024 | May 31, 2024 | -$41.64M | – |
| Q1 FY2024CQ1 2024 | Feb 29, 2024 | -$44.84M | – |
| Q4 FY2023CQ4 2023 | Nov 30, 2023 | $24.10M | – |
| Q3 FY2023CQ3 2023 | Aug 31, 2023 | -$43.59M | – |
| Q2 FY2023CQ2 2023 | May 31, 2023 | -$19.55M | – |
| Q1 FY2023CQ1 2023 | Feb 28, 2023 | -$50.73M | – |
| Q4 FY2022CQ4 2022 | Nov 30, 2022 | -$40.52M | – |
| Q3 FY2022CQ3 2022 | Aug 31, 2022 | -$49.73M | – |
| Q2 FY2022CQ2 2022 | May 31, 2022 | -$35.70M | – |
| Q1 FY2022CQ1 2022 | Feb 28, 2022 | -$46.10M | -739.4% |
| Q4 FY2021CQ4 2021 | Nov 30, 2021 | -$31.77M | – |
| Q3 FY2021CQ3 2021 | Aug 31, 2021 | -$31.84M | – |
| Q2 FY2021CQ2 2021 | May 31, 2021 | -$33.63M | – |
| Q1 FY2021CQ1 2021 | Feb 28, 2021 | $7.21M | -82.2% |
| Q4 FY2020CQ4 2020 | Nov 30, 2020 | -$21.39M | – |
| Q3 FY2020CQ3 2020 | Aug 31, 2020 | -$7.81M | – |
| Q2 FY2020CQ2 2020 | May 31, 2020 | -$16.04M | – |
| Q1 FY2020CQ1 2020 | Feb 29, 2020 | $40.61M | – |
| Q4 FY2019CQ4 2019 | Nov 30, 2019 | -$13.70M | – |
See a number that looks wrong?